Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.21.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2017
Jun. 30, 2021
Jun. 30, 2021
Dec. 31, 2018
Loss Contingencies [Line Items]        
Number of warrants       6,000
Warrants and Rights Outstanding, Term       5 years
Exercise price per share       $ 1.00
License Agreement [Member] | QSAM Therapeutics Inc [Member]        
Loss Contingencies [Line Items]        
Payments for milestone $ 60,000      
Other Expenses $ 150,000   $ 60,000  
Equity Method Investment, Ownership Percentage 5.00%      
Royalty percentage 4.50%      
Consulting fee     8,500  
Payment for license fees     60,000  
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member]        
Loss Contingencies [Line Items]        
Royalty percentage 50.00%      
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Upon Commercialization [Member]        
Loss Contingencies [Line Items]        
Other Expenses $ 1,500,000      
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Drug Development Costs Paid to Service Providers [Member]        
Loss Contingencies [Line Items]        
Development Costs, Period Cost   $ 147,453 $ 221,407  
Services Agreement [Member]        
Loss Contingencies [Line Items]        
Number of warrants       6,000
Warrants and Rights Outstanding, Term       5 years
Exercise price per share       $ 1.00